Page last updated: 2024-08-24

triptonide and Pancreatic Neoplasms

triptonide has been researched along with Pancreatic Neoplasms in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Cao, Z; Du, L; Han, H; Zhang, B; Zhou, Q1
Cao, Z; Chen, B; Li, Y; Meng, M; Xiang, S; Xu, X; Yang, P; Zhang, B; Zhang, T; Zhao, Z; Zhou, Q1

Other Studies

2 other study(ies) available for triptonide and Pancreatic Neoplasms

ArticleYear
Triptonide potently suppresses pancreatic cancer cell-mediated vasculogenic mimicry by inhibiting expression of VE-cadherin and chemokine ligand 2 genes.
    European journal of pharmacology, 2018, Jan-05, Volume: 818

    Topics: Antigens, CD; Antineoplastic Agents; Cadherins; Cell Line, Tumor; Chemokine CXCL2; Drug Discovery; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Invasiveness; Neoplasm Metastasis; Neovascularization, Pathologic; Pancreatic Neoplasms; Triterpenes

2018
Selective activation of tumor-suppressive MAPKP signaling pathway by triptonide effectively inhibits pancreatic cancer cell tumorigenicity and tumor growth.
    Biochemical pharmacology, 2019, Volume: 166

    Topics: Animals; Carcinogenesis; Enzyme Activation; Female; Humans; MAP Kinase Signaling System; Mice; Mice, Inbred NZB; Mice, SCID; Mitogen-Activated Protein Kinase Kinases; Pancreatic Neoplasms; Random Allocation; Treatment Outcome; Triterpenes; Tumor Burden; Xenograft Model Antitumor Assays

2019